Chimeric Protein Immunogen for P. gingivalis Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to elicit a strong protective immune response against Porphyromonas gingivalis infection due to the complexity of its virulence factors, which are difficult to express and present in a conformation similar to the native protein, and the relative immunogenicity of epitopes is not well understood.
Innovation Solution
A chimeric or fusion protein is developed, comprising peptides that share homology with regions of Porphyromonas gingivalis trypsin-like enzymes, specifically the catalytic site, joined to adhesin domains, to induce a humoral response and provide protection against alveolar bone loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional virulence factors are used as immunogens, then the immune response can be elicited, but the protective response is insufficient due to the complexity and difficulty of expressing virulence factors in native conformation
Solution Approach 1:
The patent divides the complex P. gingivalis virulence factors into specific functional domains (catalytic domain, adhesin domain, hemagglutinin domain) and expresses them as separate chimeric proteins. This segmentation allows each domain to be optimized independently for immunogenicity while maintaining the protective response, resolving the contradiction between eliciting immune response and managing the complexity of complete virulence factors.
Solution Approach 2:
The patent creates chimeric proteins that copy key functional domains of P. gingivalis virulence factors using recombinant DNA technology. These chimeric proteins replicate the critical immunogenic features of native virulence factors without requiring expression of the complete complex virulence factor profile, thereby simplifying the immunogen while maintaining protective immunity.
2Ease of manufacture
If virulence factors are expressed as discrete units in isolation, then expression is simplified, but the conformation differs from native P. gingivalis structure
Solution Approach 1:
The patent merges multiple functional domains (catalytic domain, adhesin domain, hemagglutinin domain) into chimeric proteins that maintain their native conformations. By combining these domains in a unified protein structure rather than expressing them as isolated units, the patent achieves both ease of manufacture and conformational accuracy, as the domains are presented in their native three-dimensional arrangement.
3Adaptability or versatility
If multiple virulence factor domains are used, then the immune response coverage is increased, but the relative immunogenicity of epitopes becomes unclear
Solution Approach 1:
The patent applies local quality by creating chimeric proteins where specific domains (catalytic, adhesin, hemagglutinin) are highlighted with enhanced immunogenicity. Each domain is presented with its characteristic epitopes in a controlled manner, allowing the relative immunogenicity of each region to be clearly defined and understood, while still providing broad coverage across multiple virulence factors.
Data Source
AI summary
Disclosed are P. gingivalis antibodies raised against a chimeric or fusion protein, wherein the chimeric or fusion protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.